This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD33. It is a humanized monoclonal antibody used in the treatment of cancer.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-321-sdAb | Recombinant Anti-human CD33 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
Excellent for Studying Cancer Cells
Lintuzumab has been transformative for our research on CD33-positive cancer cells. Its enhanced ADCC capability has allowed us to study immune responses more effectively, laying the groundwork for potential new therapies.
High Specificity
Lintuzumab consistently demonstrates high specificity for CD33, with minimal off-target effects. This specificity ensures our results are accurate, making it indispensable for our CD33-positive cancer research.
Robust Functional Analysis
The data we've gained from using Lintuzumab in functional assays has been robust and reliable. It has played a crucial role in understanding ADCC dynamics and the therapeutic targeting of CD33-positive cells.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.